Search

Your search keyword '"Canuso,Carla"' showing total 281 results
Start Over Author "Canuso,Carla"
281 results on '"Canuso,Carla"'

13. Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Depressive Symptoms in Adolescents With MDD at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Psychoactive-Controlled Study

Author

DelBello, Melissa P., primary, Kosik-Gonzalez, Colette, additional, Fu, Dong-Jing, additional, Chen, Li (Nancy), additional, Lane, Rosanne, additional, Drevets, Wayne C., additional, Moreno, Carmen, additional, and Canuso, Carla M., additional

Published
2023
Full Text
View/download PDF

15. Suicide‐specific mortality among patients with treatment‐resistant major depressive disorder, major depressive disorder with prior suicidal ideation or suicide attempts, or major depressive disorder alone

Author

Kern, David M., primary, Canuso, Carla M., additional, Daly, Ella, additional, Johnson, Jonathan C., additional, Fu, Dong Jing, additional, Doherty, Teodora, additional, Blauer‐Peterson, Cori, additional, and Cepeda, M. Soledad, additional

Published
2023
Full Text
View/download PDF

17. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant in Adult Patients with Treatment-Resistant Depression: A Randomized, Double-Blind, Multicenter, Active-Controlled Study Conducted in China and USA

Author

Chen,Xu, Hou,Xuan, Bai,Daisy, Lane,Rosanne, Zhang,Chong, Canuso,Carla, Wang,Gang, Fu,Dong-Jing, Chen,Xu, Hou,Xuan, Bai,Daisy, Lane,Rosanne, Zhang,Chong, Canuso,Carla, Wang,Gang, and Fu,Dong-Jing

Abstract

Xu Chen,1,2,* Xuan Hou,3,* Daisy Bai,4 Rosanne Lane,5 Chong Zhang,6 Carla Canuso,7 Gang Wang,1,2 Dong-Jing Fu7 1The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, People’s Republic of China; 2Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, People’s Republic of China; 3Clinical Development, Janssen China Research & Development, Shanghai, People’s Republic of China; 4Statistics, Janssen China Research & Development, Shanghai, People’s Republic of China; 5Statistics, Janssen US Research & Development, Titusville, NJ, USA; 6Clinical Pharmacology, Janssen China Research & Development, Shanghai, People’s Republic of China; 7Neuroscience, Janssen US Research & Development, Titusville, NJ, USA*These authors contributed equally to this workCorrespondence: Gang Wang, The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital and Advanced Innovation Center for Human Brain Protection, Capital Medical University, 5 Ankang Hu Tong, Beitaipingzhuang, Xicheng District, Beijing, 100035, People’s Republic of China, Tel +86 010-58303189, Email gangwangdocvip@163.com Dong-Jing Fu, Neuroscience, Janssen US Research & Development, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA, Tel +1 609 730 4312, Email dfu@its.jnj.comPurpose: This Phase 3, multicenter study (NCT03434041) was conducted in primarily Chinese patients with treatment-resistant depression (TRD) to support the registration of esketamine nasal spray in China.Patients and Methods: This randomized, double-blind, active-controlled study was conducted in China and the United States (US) in patients with TRD (single or recurrent episode). Eligible patients were randomized 1:1 to receive intranasal esketamine or matching placebo, each

Published
2023

18. A Meta-Analysis of the Antidepressant Responses in Pivotal Trials on Esketamine Nasal Spray and Atypical Antipsychotics

Author

Wang,Lien, Chen,Xiaowei, Gu,Xiaojing, De Smedt,Heidi, Popova,Vanina, Fu,Dong-Jing, Canuso,Carla, Drevets,Wayne, Chen,Guang, Wang,Lien, Chen,Xiaowei, Gu,Xiaojing, De Smedt,Heidi, Popova,Vanina, Fu,Dong-Jing, Canuso,Carla, Drevets,Wayne, and Chen,Guang

Abstract

Lien Wang,1,2 Xiaowei Chen,1 Xiaojing Gu,1 Heidi De Smedt,3 Vanina Popova,3 Dong-Jing Fu,4 Carla M Canuso,4 Wayne C Drevets,2 Guang Chen2 1Janssen Research & Development, LLC, Janssen Pharmaceutical Companies of Johnson & Johnson, Shanghai, People’s Republic of China; 2Janssen Research & Development, LLC, Janssen Pharmaceutical Companies of Johnson & Johnson, Brisbane, CA, USA; 3Janssen Research & Development, LLC, Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium; 4Janssen Research & Development, LLC, Janssen Pharmaceutical Companies of Johnson & Johnson, Raritan, NJ, USACorrespondence: Guang Chen, Janssen Fellow, Scientific Director, Translational Research, Mood DAS, Neuroscience Therapeutic Area, Janssen R & D, LLC, Janssen Pharmaceutical Companies of Johnson and Johnson, 3210 Merryfield Row, Room 1908, San Diego, CA, 92121, USA, Tel +1 (240) 602 7950, Email guangchenmd@gmail.comPurpose: This meta-analysis assessed whether atypical antipsychotics (AAPs) and esketamine nasal spray (ESK-NS), which are mechanistically distinct, differ in antidepressant outcomes.Patients and Methods: Data were extracted from 12 trials of ESK-NS or AAPs in depressed patients (4276) with inadequate response or resistance to conventional antidepressants. Montgomery-Åsberg Depression Rating Scale (MADRS) score reductions from baseline and response rates (≥ 50% reduction) were analyzed.Results: At endpoint, the estimated MADRS score reduction of pooled ESK-NS arms was greater than pooled AAP arms (+9.16 points, p < 0.0001). The reduction also was greater in the pooled control arms of the ESK-NS trials than the pooled control arms of the AAP trials (+7.57 points, p < 0.0001). The mean difference in the reductions between pooled ESK-NS and control arms was 1.87 points greater than that between pooled AAP and control arms, but this difference was not significant (95% CI: − 4.49, 0.74, p = 0.16). Relative to their respectiv

Published
2023

19. Efficacy and safety of JNJ-42165279, a fatty acid amide hydrolase inhibitor, in adolescents and adults with autism spectrum disorder: a randomized, phase 2, placebo-controlled study

Author

Klein, Matthew E., Bangerter, Abigail, Halter, Robin J., Cooper, Kim, Aguilar, Zuleima, Canuso, Carla M., Drevets, Wayne C., Schmidt, Mark E., and Pandina, Gahan

Abstract

JNJ-42165279, a highly selective and orally bioavailable fatty acid amide (FAA) hydrolase inhibitor, was evaluated for efficacy and safety in adolescents and adults with autism spectrum disorder (ASD) in this phase 2, double-blind, placebo-controlled, multicenter study (NCT03664232). Participants aged 13–35 years, with a diagnosis of ASD (Diagnostic and Statistical Manual of Mental Disorders, 5th edition; Autism Diagnostic Observation Schedule, 2nd edition) were randomized (1:1) to 12 weeks of treatment with JNJ-42165279 (25 mg, twice-daily) or placebo. Primary endpoints were the change in the Autism Behavior Inventory (ABI) Core Domain (ABI-CD), ABI-Social Communication (ABI-SC), and ABI-Repetitive/Restrictive Behavior (ABI-RB) scores from baseline to day 85. Of the 61 participants (16 female, 45 male) included in the efficacy analyses, 53 (87%) completed the double-blind treatment. At day 85, the JNJ-42165279 group did not show a statistically significant reduction in ASD symptoms versus placebo, as assessed with ABI-CD (p= 0.284), ABI-SC (p= 0.290), and ABI-RB (p= 0.231). However, the following secondary outcomes exhibited small to moderate changes directionally favoring JNJ-42165279: Social Responsiveness Scale 2 (SRS, p= 0.064), Repetitive Behavior Scale-Revised (RBS-R, p= 0.006), Zarit Burden Interview short version (ZBI, p= 0.063), Child Adolescent Symptom Inventory-Anxiety (CASI-Anx, p= 0.048), and Caregiver Global Impression of Severity (p= 0.075). Notably, versus placebo, JNJ-42165279-treated participants showed increased concentrations of FAAs throughout the treatment period, with those achieving elevated concentrations experiencing the greatest reduction in the SRS total score at day 85. JNJ-42165279 demonstrated an acceptable safety profile. Although primary endpoints were not met, JNJ-42165279 may have a therapeutic effect on certain aspects of core ASD symptoms.

Published
2024
Full Text
View/download PDF

20. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant in Adult Patients with Treatment-Resistant Depression: A Randomized, Double-Blind, Multicenter, Active-Controlled Study Conducted in China and USA

Author

Chen, Xu, primary, Hou, Xuan, additional, Bai, Daisy, additional, Lane, Rosanne, additional, Zhang, Chong, additional, Canuso, Carla, additional, Wang, Gang, additional, and Fu, Dong-Jing, additional

Published
2023
Full Text
View/download PDF

23. Treatment of Schizophrenia

Author

Woo, Tsung-Ung, primary, Canuso, Carla, additional, Wojcik, Joanne, additional, Noordsy, Douglas, additional, Brunette, Mary, additional, and Green, Alan, additional

Published
2017
Full Text
View/download PDF

24. Commentary on Cochrane review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder".

Author

Borentain, Stephane, Desai, Pooja, Fu, Dong-Jing, Nancy Chen, Li, Lane, Rosanne, Mathews, Maju, and Canuso, Carla M

Subjects
MENTAL depression, KETAMINE, GLUTAMATE receptors, SUICIDAL ideation, SUICIDE risk factors, ANTIDEPRESSANTS
Abstract

Background: Cochrane recently published a review of esketamine and other glutamate receptor modulators in depression. Aim: To address the limitations of the review, analyses of esketamine data were conducted to provide additional perspective to the reviewers' interpretation of their findings. Methods: Response rate, remission rate, and change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score were determined using data from all esketamine phase 2/3 registration studies of treatment-resistant depression (TRD) and, separately, all esketamine phase 2/3 registration studies of major depressive disorder (MDD) and active suicidal ideation with intent. Outcomes were assessed at all timepoints (i.e., 24 h, 72 h (MDD with active suicidal intent only), and 1, 2, and 4 weeks). Enrollment criteria of the TRD studies were different than those of the studies of MDD and active suicidal ideation with intent, resulting in differences in patients' clinical characteristics and depression severity between the cohorts. Thus, we did not compare results between these cohorts (as was done in the Cochrane review). Results/outcomes: In the combined TRD studies, a statistically significant between-group difference favored esketamine plus antidepressant over antidepressant plus placebo at 24 h (based on response, remission, and change in MADRS score), 1 week (change in MADRS score), 2 weeks (response and change in MADRS score), and 4 weeks (response, remission, and change in MADRS score). In the combined studies of MDD and active suicidal ideation with intent, the between-group difference was statistically different, favoring esketamine plus standard-of-care over placebo plus standard-of-care, at 24 h (response, remission, and change in MADRS score), 72 h and 1 week (change in MADRS score), 2 weeks (response), and 4 weeks (response, remission, and change in MADRS score). For both study types, the between-group difference in outcomes was not statistically significant at the other timepoints. Conclusions/interpretation: Esketamine improves response, remission, and depressive symptoms as early as 24 h post-first dose among patients with TRD and among patients with MDD and active suicidal ideation with intent. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

25. Veteran Adherence to Oral Versus Injectable Alcohol Use Disorder Medication Treatment

Author

Dorflinger, Charles, Carey, Heather, Roche, Jennifer, Burant, Christopher, LeHew, Colleen, Stewart, Hayden, Mitchell, Brian, Ayanga, Daniel, Walder, Annette, Cooler, Jordan, Wu, Shuwen, Frey, Theresa, Wenthur, Cody, Burk, Bradley, Ward, Alex, Clark, Brooke, Leung, Jonathan G, Kutzke, Jade, May, Heather P, Maehler, Colin, Kummer, Bethany, Hamner, Jennifer, Ariefdjohan, Merlin, Stutzman, Danielle L, Kicklighter, Jackson, Musco, Shaina, Singson, Grace Marielle, Pamintuan, Claire, Francisco, Janelle, Phan, Tam, Sevak, Rajkumar J, Rogan, Edward L, Kehoe, William A, Halliwell, Robert F, Kanter, Joel, Ryan, Holly, Patel, Krupa, Moukaddam, Nidal, Saunders, John, Fernandez, Luis, Shah, Asim, Wong, Jerry, Erowele, Goldina, Ruppelt, Sara, Tillery, Erika E, Baker, Joni, Loflin, Bobbi Jo, Gray, Emily, Conley, Giulia, Hembree, Amanda, Sterling, Jacyntha, Buige, Ashley N, Nguyen, Mimi, Harris, Suzanne C, Bhavsar, Nisha, Shah, Niti, Lee, Bona, Jeong, Seoyoung, Maroney, Megan E, Whalen, Eric D, Maloney, Rebecca M, Hagemeier, Nicholas E, Takamura, Kay, Rice, Amanda G, Furbish, Amelia B, Hebbard, Amy M, Ross, Clint, Cumbie, Holly, Hickey, J. Scott, Lalani, Falak, Mucha, Hannah, Saklad, Stephen R, Ma, Connie, Lee, Kelly, O’Donnell, Carolyn, Jackson, Sarah, Albee, Jennifer Nelson, Yapel, Ann, Nash, Cynthia, MacDonald, Danielle, King, Amelia, Schneiderhan, Mark, Hager, Keri, Bell Lynum, Karimah S, Nash, Abigail, Fu, Dong Jing, Ionescu, Dawn F, Sliwa, Jennifer Kern, Turkoz, Ibrahim, Dorson, Peter G, Canuso, Carla, Hsia, Stephanie, Nguyen, Julie, La, Amenda, Gruenberg, Katherine, MacDougall, Conan, Brockbank, Josh, Wong, Kara, Schultz, Erica, Pinchinat, Jessica, Thibeaux, Taylor M, McCants, Tamara, Lam, Jason, Diaz-Luna, Jose, Nguyen, Jennifer, Yokoyama, Melissa, Albiar, Olivia, Bradley, Bridget, Popish, Sarah J, Bounthavong, Mark, Lau, Marcos K, Wells, Daina L, Kay, Chad L, Harvey, Michael A, Himstreet, Julianne E, Christopher, Melissa L.D, Weeda, Erin R, McGraw, Daniel J, Gonzalez, Misty L, Pardo-Pfeiffer, Carlos, Rodeghiero, Abigail, Zhang, Lusi, Brown, Sarah Jane, Shan, Yuting, Lee, Adam M, Allen, Josiah D, Eum, Seenae, Bishop, Jeffrey R, Gonzalez, Rolando, Wahl, Kimberly, Naglich, Andrew, Ayson, Marl, Thomas, Kelan, Renfro, Mandy L, Loera, Lindsey J, Hill, Lucas G, Tirado, Carlos, Delerme, Dante, Dean, Taylor, Cullen, Marissa, Straley, Craig M, Carr, Chelsea N, Sun, Wendy, Alzouby, Hiba, Harris, Suzanne, Banker, Christopher M, Cook, Sarah F, Muir, Justin, Brodie, Daniel, Cremers, Serge, Bies, Robert R, Dzierba, Amy L, Moton, Robert, Saklad, Stephen, Ferris, Ryan E, Noble, Brie N, Hartung, Daniel M, Tjia, Jennifer, Furuno, Jon P, Ibrahim, Hajer, Duong, Dat, Malcolm, Benjamin, Gogineni, Hyma P, Zahn, Amy L, Alibeckoff, Chloe C, Connor, Sharon, Buranosky, Raquel, Livezey, Sabrina N, Daniell, Jessica, DeClercq, Josh, Choi, Leena, Zuckerman, Autumn, Shah, Nisha B, Kang, Ashley, Anksorus, Heidi, Troglin, Courtney G, Bouldin, J. Brooke, Schreiner, Shannon, McKinney, Mariah, Brown, Stacy D, Pond, Brooks B, Nguyen, Thu, Chin, Hyun Ji, Dambly, Nicolle, Augsten, Alberto, Themas, Samantha, Vicencio, Claudia, Horner, Caroline, Covert, Kelly, Lewis, Paul, Tharp, Jen, Sommi, Roger W, Bidollari, Ilda, Still, Daniel, Du, Yangchun, Yagoda, Sergey, Weiden, Peter J, Long, Katelyn, Vandiver, Emily, Johnson, Stephanie, Darazs, Brooks, Tillery, Erika, Silvia, Richard J, Lee, Kelly C, Bien, Ivy, Farahmand, Khodayar, Goldsmith, Hannah, Farrar, Mallory, Le, Hadley, Huynh, Quynh, Kim, Jane, McCausland, Kristen, Haider, Batool, White, Michelle K, O’Sullivan, Amy K, Rychlec, Kaitlin, Akerman, Sarah, Fratantonio, James, Saxon, Andrew, Thase, Michael E, Parikh, Sagar V, Maheshwari, Priya, Rothschild, Anthony J, Dunlop, Boadie W, DeBattista, Charles, Conway, Charles R, Forester, Brent P, Shelton, Richard C, Macaluso, Matthew, Brown, Krystal, Li, James, Jablonski, Michael R, Greden, John F, Gidal, Barry, Patsalos, Philip, Szaflarski, Jerzy, VanLandingham, Kevan, Critchley, David, Morrison, Gilmour, Weiss, Catherine, Meehan, Stine Rasmussen, Ouyang, John, Hobart, Mary, Rowe, William, Vanover, Kimberly E, Kane, John M, Satlin, Andrew, Durgam, Suresh, Davis, Robert E, Mates, Sharon, Correll, Christoph U, Tamminga, Carol, Rabon, Hannah, Smith, Jordan, Squires, Karrie, VanDaele, Madeline, Logan, Linda D, Zhang, Feng, DeSousa, Norberto J, Sallee, F. Randy, Lickrish, David, Incledon, Bev, Smith, Joseph L, Candon, Molly, Fadeyibi, Oluwatoyin, Connolly, K. Ryan, Lim, Suet, Neimark, Geoffrey, Mandell, David, Newcomer, John W, Silverman, Bernard, DiPetrillo, Lauren, Graham, Christine, Jiang, Ying, Simmons, Adam, Hopkinson, Craig, McDonnell, David, Kahn, Rene, King, Thomas R, Kando, Judith C, Pardo, Antonio, King, Thomas, Edwards, John B, Chen, Richard, Huo, Jason, Cutler, Andrew J, Fawver, Jay, Flanagan, Mindy, Smith, Thomas, Drouin, Michelle, Mirro, Michael, Yatham, Lakshmi N, Vieta, Eduard, McIntyre, Roger S, Jain, Rakesh, Earley, Willie R, Patel, Mehul, Brown, Lisa, Sehgal, Rahul, Yu, Ken, Al Habbab, Talal, Johnson, Holly, Dechairo, Bryan, Chen, Jack J, Singer, Carlos, Marder, Stephen R, Comella, Cynthia L, Shah, Chirag, Jimenez, Roland, Goodwin, Heather, Morrow, Gina, Tewksbury, Ashley, Waters, Kristin, Eggert, Robyn, Tallian, Kimberly, Sepulveda, Joe A, Rojas, Sarah, Sikand, Harminder, Sutera, Nathan, Iuppa, Courtney A, Nelson, Leigh Anne, Kriz, Carrie R, Burns, Nicole A, Lang, Shelby E, Elliott, Ellie S.R, Luong, Uyen, Elsobky, Teresa, Abelleira, Audrey, Awan, Sundus, Dume, Roberta, Dilich, Adam, Anderson, Mikaela, Park, Priscilla, Moehnke, Austin, Aebi, Cydreese, Feighner, Lydia, Vernon, Martein, Streit, Jessica, Kauer, Jill, Lemons, Amber, Diefenderfer, Lauren A, Moon, Joseph, Smith, Jordan O, Franck, Hugh A, Randle, C. Hope, Hedgepeth Kennedy, M. Lindsey, James, Shannon, Coplan, Benjamin, Ruekert, Laura, Puri, Shilpa, Yeleti, Ramya, Cathright, Sela, Coveart, Stephanie, Regen, Sloan, Stewart, Shannon, Stratton, Miranda, Haight, Robert, Hoeft, Dawn, Bishop, Danielle, De La Cruz, Austin, Aurelio, Mariellee, Prestenback, Autumn, Price, Paul L, Makuch, Christian X, Salisbury, Nicole M, Koch, Jessa, Palmer, Melissa C, Chace, Ashley, Price, Cristofer, Putney, Jessica, Khan, Fatima, Huntsman, Amanda, Hutcheson, Brooklyn, Hightower, Sharae, Ott, Carol A, Scott, Catherine, Balser, Amanda, Karas, Andrew, Hsu, Michael, Malin, Maureen, Robert, Sophie, Leung, Edwina, Mierzwa, Mark, Kay, Lehua, Bowling, Dalia, Allen, Sabrina, Weingartner, Melissa, Ventricelli, Daniel, Santa, Heather, Nowalk, Alexandra, Downs, George, Le, N, Mospan, C, Burton, Caitlin, Mathys, Monica, Gutierrez, Erika, Ali, Sarah, Chang, Joni, Holzum, Dorothy N, Griffith, June A, Morgan, Katherine T, Laguado, S. Andrea, Steavenson, Rosana, Mehvar, Mina, Bechtold, Carson L, Kim, Heesoo, Dopheide, Julie Ann, Anderson, Lindsey, Kleyn, Thomas, DiRenzo, Baely, Walroth, Todd, Adamczyk, Raechel, Kendrick, Jenna, Thomas, Christopher, Mailloux, Lindsay M, Haas, Matthew T, Larew, Janel M, Stohs, Matthew E, DeJongh, Beth M, Satow, Britney A, Titus-Lay, Erika, Clark, Suzanne, Dike, Dozie, Pinsonnault, John, Gamber, Joy, Roseberry, Samantha, Mitchell, Brian G, Nguyen, Mai, Willborn, Robert, Roche-Desilets, Jennifer, Dailey, Alison, Ignatowski, Michael, Routhieaux, Melanie, Kawsky, Jaclyn, Stratman, Jennifer, Corboy, Alexander, Norberte, Cherisse, Gross, Tonya, Daniel, Jeremy, Tran, Aaron N, Wary, Megan, Kostric, Anna, Schaller, Samantha, Shin, Yunjung, Maroney, Megan, Hampton, Chanese, Krieger, Kelly, Hartwig, Rachel, Thamawatanakul, Rani, Wilbur, Eileen, Shofner, Steven, Butler, Justin, Moody, Breanna, Davis, Elizabeth, Hofammann, Elizabeth, Liveoak, Katie, Mitchell, McKinley, Lebrecht, Morgan, Hawley, Joanne, Smigiel, Joe, Radtke, Michelle, Walkerly, Autumn, King, Morgan, Wakefield, Andrew, Downs, Mona, Hudson, Nancy, Burghart, Steven, Reynoldson, Jill, Booth, Macey, Ishino, Risa, Lee, Tammie, Wright, Melissa, Boggs, Angela, Kaur, Rajandeep, Patel, Parth, Smith, Thomas R, Theriault, Sarah, Okusaga, Olaoluwa, Reinstatler, Kristina, Hawk, David, Rush, Stephen, Vachuska, Michaela, Powell, Elizabeth, Lacro, Jonathan, Chehovich, Charisse, Demler, Tammie Lee, deRosas, Andrea, Trigoboff, Eileen, Taylor, Aminah, Singh, Divita, Burdge, Gary, Reynolds, Jamie, Kriz, Carrie, Burns, Nicole, Sommi, Roger, Yabs, Melanie, Sarpal, Deepak, Fabian, Tanya, Bartos, Lindsey, Tallman, Kristin, Johnson, Dara, Taylor, Daniel, Hogan, Brendon, Kwan, Peter, Bast, Aubree, Sanchez, Apolinar, Maglalang, Patricia D, Scheible, Mahli M, Skurat, McKenzie K, Jackson, Sarah K, Belknap, Jazmin N, Ostfeld, Larissa, Fahy, Megan, Nguyen, Tuyen, Bui, Hoa, Little, Meg M, Seifert, Randall, Maister, Ashley, McCarthy, Caitlin, Burger, Emily, Mullen, Sandy, Cusimano, Joseph, VandenBerg, Amy, Duquette, Meghan, Guttenberg, Viktoria, Matsunaga, Candace, White, Shelby, Richard, Andrea, Jones, Jessica, Morgan, Kaitlyn, Kelsey, Taylor, Sartin, Carrie J, Rickert, Leah, Ferrill, Laine, Vallabh, Anuja, Jhawar, Archana, Barrett, Monica, Ward, Sarah, Colvard, Michelle, Phan, Joann, Preinitz, Jennifer, Ellis, Marcus, Gibu, Matthew, Kivlehan, Audrey, Chiulli, Dana, Rhodes, Kirby, Brewer, T. Amber, Richard, Michelle, Kirwan, Brigit, Flowers, Gary, Albritton, Melinda, Sutton, Caroline M, McEachern, Sydney, Miskle, Benjamin, Barr, Rachel, Thomas, Chris, Yang, Waverly, Vogt, Caitlin, Charles, Amanda, Mathews, Alisha, Bhandari, Deepali, Olsen, Emily, Garling, Ashley, Liszka, Jessica, Goodman, Courtney S, Smith, Tammy, Barron, Ana, Williams, Andrew, Zuloaga, Andrea, Parra, Brianne, Miller, Joy, Blake, Jennifer, Toney, Gregory, Galeano, Kathleen, Morabito, Brianna, Smith, Sydney, Miller, Lindsey, Fleisch, Sheryl, Kim, Erika, Kurz, Troy, Peterson, Angela M, Gruca, Justin, McGuire, Michael, Stummer, Lauren, Yip, Agustin, Rodriguez-Villa, Fernando, Wilson, Jennifer, Sutton, Caroline, Owings, R. Laney, Herbst, Claire, Hosmer, Kane, Wulff-Burchfield, Elizabeth, Ramion, Shelby, Brown, Lauren, Shishko, Ilona, Allen, Sarah, Nichols, Taylor, Fawcett, Janet, Trent, Kelley N, Eatmon, Courtney V, Hershberger, Allie, Roads, Mary, Pittenger, Amy L, Dadebo, Victoria, Tomko, John R, Simeone, Danielle, Sherwood, Devon A, Morgan, Katherine, White, C. Whitney, Holzum, Dorothy, Adetunji, Oluwaseyi, Blalock, Meredith, Snyder, Sabrina Domicoli, Kneebusch, Jamie, Mitchell, Melissa, Butala, Niyati, McHugh, Trisha, McGuire, J Michael, Moller, Karen, Melton, Brittany, Mitchell, Melissa M, Chaplin, Kyrsten, Canto, Samantha, Hang Vu, Thi Thuy, Rey, Jose A, Elmaoued, Amre Adel, Hopper, Jessica, Do, Annette, Leckband, Susan G, Abraham, Dana L, Haught, Emma J, Kobulinsky, Lawrence R, Fabian, Tanya J, Greenwood, Jessica, Rey, Jose, Chen, Emily, Farhadian, Sanaz, Smith, Austin M, Hopkins, Tiffany M, Deardorff, O. Greg, Jenne, Victoria, Wood, Joshua, Trout, Megan, Beck, Niels C, Pals, Hale, Frazier, Erica, Cavaliere, Vincent S, DiPaula, Bethany A, Glassman, Matthew, Wehring, Heidi J, Mackowick, Marie, Park, Jaeboon, Love, Raymond C, Kelly, Deanna L, Newbold, Mervan, Fioravanti, Nicole, Brown, Matthew J, Casey, Emily R, Nadkarni, Neha, Oh, Sarah, Patel, Romi, Riedley, Taylor, Mathis, Erin, Fadden, Patrick, Madden, Cristina, Schneiderhan, Mark E, Hintsala, Madelynn, Stenehjem, David, Rufus, Krystal M, Elhakim, Athar, Zolezzi, Monica, Elamin, Waad M, Homs, Shorouk, Qubaiah, Iman K, Mahmoud, Doaa A, Tawfik, Enge M, Fritz, Merideth, Alman, Brianne, Wartman, Carolanne, Clark, Megan, Ott, Carol, Rainey, Carly A, Mann, Elise, Modany, Madison, Schoettmer, Amanda, Buckley, Tiffany, Patwardhan, Vidisha, Boyle, Cynthia J, Gardner, Kristen N, Hamby, Kerri, Ngo, Nichol, Kim, Lila Q, Chen, Steven W, Mosley, Scott, Dadiomov, David, Goldstone, Lisa W, DellaVecchia, Matthew J, Cauffield, Jacintha, Grim, Hannah, Eschler, Anna, Aladeen, Traci, Blondell, Richard, Capote, Horacio, Rainka, Michelle, Lee, Ashley, Shelley, Maria, Stoncius, Kristina, Berry, Jonathan, Doroudgar, Shadi, Johnson, Kayla, Pouliot, Jonathon, Rarrick, Christine, Hebbard, Amy, Shikwana, Sara, Koller, Katherine, Reed, Ellen, Hoefling, Austin D, Miles, Talia M, Ansara, Elayne D, Titova, Viktoriya, Kandela, Dalea, Douglass, Amber R, Ehrhard, Kimberly, Stanley, Madison, Ganihong, Carissa, Liu, Mei T, Bohnenberger, Kristin, Zuber, Nicole, Plunkett, McKenzie, Axelrod, Chelsey, Lightfoot, Myaa, Moore, Miranda, Crouse, Ericka, Olazo, Muriel, Taormina, Stephanie, Reiss, Rebecca, Denno, Nora, Johnson, Braniesha, Wilkening, Gwendolyn Lucy, Andrews, Haley, Neumeister, Kristen, Murad, Muhammad Ubaidullah, Reid, Bailey, Franco, Ashley, Stutzman, Danielle, Jorgensen, Jennifer, Basit, Saadia, Jensen, Aimee, Nadal, Celeste N, Truong, Quynh-Nhu, Jameson, Melanie, Knox, Erin D, Bota, Robert G, Wieruszewski, Patrick M, and Leung, Sarah B

Subjects
CPNP Foundation Strategic Goals Award Finalists, Therapeutic Case Report Abstracts, Original Research Abstracts, Therapeutic Case Report Award Finalists, Article, Encore Presentation Abstracts, Work in Progress Abstracts, Neuropsychology and Physiological Psychology, Original Research Award Finalists, Research Trainee Award Finalists, Pharmacology (medical), Neurology (clinical), General Pharmacology, Toxicology and Pharmaceutics, Innovative Practices Abstracts, Innovative Practices Award Finalists, Scientific Posters
Published
2020
Full Text
View/download PDF

28. 89. GENOME WIDE META-ANALYSIS OF SUICIDE BEHAVIORS

Author

Li, Qingqin, primary, Docherty, Anna, additional, Shabalin, Andrey, additional, DiBlasi, Emily, additional, Gopal, Srihari, additional, Daly, Ella, additional, Canuso, Carla, additional, Consortium, FinnGen, additional, Drevets, Wayne, additional, and Coon, Hilary, additional

Published
2021
Full Text
View/download PDF

34. SIBAT--A Computerized Assessment Tool for Suicide Ideation and Behavior: Development and Psychometric Properties.

Author

ALPHS, LARRY, FU, DONG, WILLIAMSON, DAVID, JAMIESON, CAROL, GREIST, JOHN, HARRINGTON, MAGDALENA, LINDENMAYER, JEANPIERRE, SMITH, CHERYL MCCULLUM, SHEEHAN, DAVID V., SHELTON, RICHARD C., WICKS, PAUL, and CANUSO, CARLA M.

Subjects
BEHAVIORAL assessment, SUICIDE risk factors, EXPERIMENTAL design, RESEARCH evaluation, COMPUTER-aided design, RESEARCH methodology, RESEARCH methodology evaluation, HEALTH outcome assessment, INTERVIEWING, SUICIDAL ideation, PSYCHOMETRICS, RISK assessment, INTER-observer reliability, INTERPROFESSIONAL relations, INTRACLASS correlation, ALGORITHMS
Abstract

Objective: Most assessments of suicidal ideation and behavior (SIB) are limited by reliance on a single assessor, typically a clinician or patient, with scant detail on patient-related drivers of SIB and inability to detect rapid change in SIB. Furthermore, many techniques do not include a semistructured interview, increasing rater variability. The Suicide Ideation and Behavior Assessment Tool (SIBAT) addresses these limitations. Design: More than 30 experts in scale development, statistics, and clinical management of suicidal patients collaborated over a greater than four-year period to develop the SIBAT. Input for content and validity was received from patients, clinicians, and regulatory authorities in the United States (US) and Europe. Psychometric properties of the SIBAT were evaluated in validation studies. Results: The SIBAT is organized into eight independent patient- or clinician-rated modules with branching logic and scoring algorithms, which necessitates computerization. Patient-reported information is first captured in Modules 1 to 5. Thereafter, an experienced clinician reviews the patient's report, conducts a semistructured interview (Module 6), and assesses the patient's suicide risk (Module 7) and optimal antisuicide management (Module 8). Input from cognitive interviews of diverse adult, adolescent, and clinician participants was incorporated into the final version of the SIBAT. Psychometric testing demonstrated good inter-rater reliability (intraclass coefficient range: 0.68-0.82), intra-rater reliability (weighted-kappa range: 0.64-0.76), and concurrent validity with other instruments for assessing SIB. Conclusion: Patient- and clinician-based assessments and the psychometric studies summarized in this report support the validity and reliability of the SIBAT for capturing critical information related to assessment of SIB in adolescents and adults at risk for suicide. [ABSTRACT FROM AUTHOR]

Published
2022

35. Treatment of Schizophrenia

Author

Woo, Tsung-Ung, primary, Canuso, Carla, additional, Wojcik, Joanne, additional, Brunette, Mary, additional, and Green, Alan, additional

Published
2009
Full Text
View/download PDF

37. Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)

Author

Ionescu, Dawn F, primary, Fu, Dong-Jing, additional, Qiu, Xin, additional, Lane, Rosanne, additional, Lim, Pilar, additional, Kasper, Siegfried, additional, Hough, David, additional, Drevets, Wayne C, additional, Manji, Husseini, additional, and Canuso, Carla M, additional

Published
2020
Full Text
View/download PDF

46. Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study

Author

Canuso, Carla M., primary, Singh, Jaskaran B., additional, Fedgchin, Maggie, additional, Alphs, Larry, additional, Lane, Rosanne, additional, Lim, Pilar, additional, Pinter, Christine, additional, Hough, David, additional, Sanacora, Gerard, additional, Manji, Husseini, additional, and Drevets, Wayne C., additional

Published
2019
Full Text
View/download PDF

47. Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis

Author

Schooler Nina, Lindenmayer Jean-Pierre, Bossie Cynthia A, Turkoz Ibrahim, and Canuso Carla M

Subjects
Psychiatry, RC435-571
Abstract

Abstract Background To compare the efficacy and tolerability of paliperidone extended-release (ER) with risperidone immediate-release using propensity score methodology. Methods Six double-blind, randomized, placebo-controlled, short-term clinical trials for acute schizophrenia with availability of individual patient-level data were identified (3 per compound). Propensity score pairwise matching was used to balance observed covariates between the paliperidone ER and risperidone patient populations. Scores were generated using logistic regression models, with age, body mass index, race, sex, baseline Positive and Negative Syndrome Scale (PANSS) total score and baseline Clinical Global Impressions–Severity (CGI-S) score as factors. The dosage range of paliperidone ER (6-12 mg/day) was compared with 2 risperidone dosage ranges: 2-4 and 4-6 mg/day. The primary efficacy measure was change in PANSS total score at week 6 end point. Tolerability end points included adverse event (AE) reports and weight. AEs with rates ≥5% and with a ≥2% difference between paliperidone ER and risperidone were identified. Results Completion rates for placebo-treated subjects in paliperidone ER trials (n = 95) and risperidone trials (n = 122) groups were 36.8% and 51.6%, respectively; end point changes on PANSS total scores were similar (p = 0.768). Completion rates for subjects receiving paliperidone ER 6-12 mg/day (n = 179), risperidone 2-4 mg/day (n = 113) or risperidone 4-6 mg/day (n = 129) were 64.8%, 54.0% and 66.7%, respectively (placebo-adjusted rates: paliperidone ER vs risperidone 2-4 mg/day, p = 0.005; paliperidone ER vs risperidone 4-6 mg/day, p = 0.159). PANSS total score improvement with paliperidone ER was greater than with risperidone 2-4 mg/day (difference in mean change score, -6.7; p < 0.05) and similar to risperidone 4-6 mg/day (0.2; p = 0.927). Placebo-adjusted AEs more common with paliperidone ER were insomnia, sinus tachycardia and tachycardia; more common with risperidone were somnolence, restlessness, nausea, anxiety, salivary hypersecretion, akathisia, dizziness and nasal congestion. Weight changes with paliperidone ER and risperidone were similar (paliperidone ER vs risperidone 2-4 mg/day, p = 0.489; paliperidone ER vs risperidone 4-6 mg/day, p = 0.236). Conclusions This indirect database analysis suggested that paliperidone ER 6-12 mg/day may be more efficacious than risperidone 2-4 mg/day and as efficacious as risperidone 4-6 mg/day. The AE-adjusted incidence rates suggest differences between treatments that may be relevant for individual patients. Additional randomized, direct, head-to-head clinical trials are needed to confirm these findings.

Published
2011
Full Text
View/download PDF

49. Predicting hospital admission and discharge with symptom or function scores in patients with schizophrenia: pooled analysis of a clinical trial extension

Author

Canuso Carla M, Dirani Riad G, Kozma Chris M, and Mao Lian

Subjects
Psychiatry, RC435-571
Abstract

Abstract Background The purpose of this analysis was to evaluate relationships between hospital admission or discharge and scores for symptom or functioning in patients with schizophrenia. Methods Data were from three 52-week open-label extensions of the double-blind pivotal trials of paliperidone extended-release (ER). Symptoms and patient function were measured every 4 weeks using the Personal and Social Performance (PSP) scale and the Positive and Negative Syndrome Scale (PANSS). The intent-to-treat analysis set was defined as open-label patients who had at least one post-baseline PSP and PANSS measurement. Time until first hospitalization was evaluated using the Cox proportional hazard model with categorical time-dependent measures for the PSP (1 to 30, 31 to 70, 71 to 100) or PANSS (< 75, ≥ 75 to < 95, ≥ 95), as well as age, gender, schizophrenia duration, and country. Similar analyses were performed for time to discharge. Results Of the 1,077 enrolled patients, 1,028 (95.5%) met study criteria; of these, 382 (37.2%) were hospitalized at open-label baseline. Compared with patients with PSP ≥ 71 group, the hazard for new hospitalization was 8.351 times greater (P = 0.0001) for patients with the poorest functioning (PSP 1 to 30) and 1.977 times greater (P = 0.0295) for patients with PSP of 31-70 compared to the ≥ 71 group. The hazard for new hospitalization was 5.457 times greater (P < 0.0001) for patients PANSS ≥ 95 and 2.316 times greater (P = 0.0027) for the ≥ 75 to < 95 group compared with the < 75 group. For patients hospitalized at baseline, the PANSS ≥ 95 patients had a discharge hazard that was 0.456 times lower than for the < 75 patients (P < 0.0001). The hazard for discharge was 0.646 times lower (P = 0.0012) for the PANSS ≥ 75 to < 95 group compared with the < 75 group. A patient's country was a significant predictor variable, with US patients being admitted and discharged faster. Conclusions Better functioning or being less symptomatic is associated with reduced risk for hospitalization and greater chance for early discharge. Treatments or programs that reduce symptoms or improve function decrease the risk of hospitalization in community patients or increase the chance of discharge for hospitalized patients.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results